IXICO has completed a fundraising
March 2026 — IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a gross capital raise of US$13.5 million. The funds will be used to support the company’s tech bio strategy, enabling IXICO to partner its platform more broadly and maximize its potential.
IXICO plc is a precision neuroscience company. Its AI-enabled neuroimaging platform supports clinical trials for neurological diseases, including Alzheimer’s and Huntington’s disease, helping biopharmaceutical companies make better and faster decisions in drug development.
Our role in the transaction
Oaklins Cavendish, one of Oaklins’ member firms in the UK, acted as the sole bookrunner and broker for IXICO plc’s US$13.5 million capital raise.
Talk to the deal team
Related deals
Tandem has completed a voluntary public tender offer for the shares of Compagnia dei Caraibi
Tandem S.r.l. has completed a voluntary public tender offer for 25.99% of the shares in Compagnia dei Caraibi S.p.A.
Learn moreICOP has transferred its listing from Euronext Growth Milan to Euronext Milan
ICOP S.p.A. has transferred its listing from Euronext Growth Milan to Euronext Milan.
Learn moreRöntgeninstitut Aarau has been acquired by Evidia
The owners of Röntgeninstitut Aarau have sold the business to Evidia Group as part of their succession planning. The former owners will remain involved in the institute and support its future development alongside Evidia.
Learn more